Lexicon Pharmaceuticals, Inc. - Common Stock (NQ:LXRX)

1.610 -0.040 (-2.42%)

Delayed Quote Updated: 4:00 PM EDT, Oct 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Lexicon Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

Lexicon Pharmaceuticals Announces Presentation of Diabetic Peripheral Neuropathic Pain Patient Insights at PAINWeek 2025

September 03, 2025

From Lexicon Pharmaceuticals, Inc.

Via GlobeNewswire

Sotagliflozin Provides Consistent Relative Risk Reduction in Heart Failure and Major Cardiovascular Events Across All Age Ranges, Including Greater Than 75, in Data Presented at the European Society of Cardiology (ESC) 2025 Congress

September 02, 2025

Oral presentation highlighted improvements in heart failure endpoints and major adverse cardiovascular events (MACE) among older adults irrespective of age

From Lexicon Pharmaceuticals, Inc.

Via GlobeNewswire

Earnings Scheduled For August 6, 2025 ↗

August 06, 2025

Via Benzinga

What Analysts Are Saying About Lexicon Pharmaceuticals Stock ↗

March 07, 2025

Via Benzinga

Lexicon Pharmaceuticals to Participate at Two Upcoming Investor Conferences

August 27, 2025

From Lexicon Pharmaceuticals, Inc.

Via GlobeNewswire

Lexicon (LXRX) Q2 Revenue Soars 1,706% ↗

August 06, 2025

Via The Motley Fool

Topics Intellectual Property

Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) Q2 2025 Earnings: Revenue Soars 482% Above Estimates, Stock Gains 9.5% ↗

August 06, 2025

Lexicon Pharmaceuticals (LXRX) reports strong Q2 2025 earnings with $28.9M revenue, beating estimates by 482%. Stock rises 9.5% on profit surprise and pipeline progress.

Via Chartmill

Lexicon Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates

August 06, 2025

From Lexicon Pharmaceuticals, Inc.

Via GlobeNewswire

Lexicon Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 6, 2025

July 23, 2025

From Lexicon Pharmaceuticals, Inc.

Via GlobeNewswire

Data Demonstrating Sotagliflozin Reduces the Risk of Clinically Important Hypoglycemic Events in Adults with Type 1 Diabetes When Added to Insulin Presented at the 85th Scientific Sessions of the American Diabetes Association (ADA)

June 23, 2025

From Lexicon Pharmaceuticals, Inc.

Via GlobeNewswire

Lexicon to Present Data at the 85th Scientific Sessions of the American Diabetes Association (ADA)

June 18, 2025

Oral presentation on study demonstrating the ability of sotagliflozin to reduce the risk of hypoglycemic events regardless of kidney function in people with type 1 diabetes

From Lexicon Pharmaceuticals, Inc.

Via GlobeNewswire

SONATA-HCM Study Design Presented at Heart Failure 2025, the Annual Congress of the Heart Failure Association of the European Society of Cardiology

May 19, 2025

From Lexicon Pharmaceuticals, Inc.

Via GlobeNewswire

A Preview Of Lexicon Pharmaceuticals's Earnings ↗

May 12, 2025

Via Benzinga

Top 2 Health Care Stocks That May Crash This Month ↗

April 25, 2025

Via Benzinga

Curious about the most active stocks on Monday? ↗

March 31, 2025

Let's dive into the action on the US markets on Monday. Here are the most active stocks that are driving the market today.

Via Chartmill

Earnings Scheduled For May 13, 2025 ↗

May 13, 2025

Via Benzinga

US Stocks Likely To Open Lower After 3-Day Fall: 'Equity Drawdown Probability Hasn't Peaked Yet,' Says Goldman Sachs Analyst ↗

March 31, 2025

U.S. stock futures fell on Monday after three consecutive days of decline on Friday. Futures of benchmark indices were lower in premarket.

Via Benzinga

While Wall Street Panicked, These 3 Hidden Small-Caps Exploded Last Week — One Surging A Jaw-Dropping 60% ↗

March 31, 2025

As uncertainties surrounding trade policies, fresh recession fears, and persistent inflation kept the markets on tenterhooks throughout the past week, a handful of small-caps defied the odds by posting...

Via Benzinga

Topics Economy

Emerging Tech Quartet – PRSO, LXRX, PRTG, RNAZ – Drive Breakthroughs Across Defense, Obesity, Oncology, and RNA Therapeutics

March 28, 2025

Via AB Newswire

Topics Intellectual Property

Top movers analysis one hour before the close of the markets on 2025-03-28: top gainers and losers in today's session. ↗

March 28, 2025

Looking for insights into the US markets one hour before the close of the markets on Friday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

Via Chartmill

Friday's session: most active stocks ↗

March 28, 2025

Curious about the most active stocks on Friday? Find out which stocks are dominating the market action!

Via Chartmill

Top movers in Friday's session ↗

March 28, 2025

Keep an eye on the top gainers and losers in Friday's session, as they reflect the most notable price movements.

Via Chartmill

What 6 Analyst Ratings Have To Say About Lexicon Pharmaceuticals ↗

March 28, 2025

Via Benzinga

12 Health Care Stocks Moving In Friday's Intraday Session ↗

March 28, 2025

Via Benzinga

Traders are paying attention to the gapping stocks in Friday's session. ↗

March 28, 2025

Let's have a look at what is happening on the US markets on Friday. Below you can find the gap up and gap down stocks in today's session.

Via Chartmill

Top movers in Friday's pre-market session ↗

March 28, 2025

The US market is yet to commence its session on Friday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.

Via Chartmill

Novo Nordisk Inks Its Second Big Obesity Deal In A Week — And It's Not For A GLP-1 ↗

March 28, 2025

The company is looking for drugs it can add to Wegovy to improve the amount of weight lost.

Via Investor's Business Daily

Nasdaq Down 100 Points; Federal Reserve's Favorite Inflation Gauge Increases More Than Expected ↗

March 28, 2025

Via Benzinga

Topics Economy

Penny Stock Lexicon Pharmaceuticals Surges On Obesity Pact Worth $1 Billion With Novo Nordisk ↗

March 28, 2025

Lexicon Pharmaceuticals granted Novo Nordisk exclusive rights to develop LX9851, an oral obesity drug, with potential milestone payments of up to $1 billion.

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

March 28, 2025

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.